Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 207.80M | 434.43M | 323.80M | 319.12M | 314.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 207.80M | 434.43M | 323.80M | 319.12M | 314.95M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 207.80M | 434.43M | 323.80M | 319.12M | 314.95M |
| SG&A Expenses | 40.29M | 43.46M | 42.56M | 40.06M | 39.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.58M | 181.59M | 174.68M | 166.88M | 166.28M |
| Operating Income | 27.22M | 252.84M | 149.11M | 152.24M | 148.68M |
| Income Before Tax | 57.09M | 279.41M | 173.08M | 172.60M | 165.44M |
| Income Tax Expenses | 894.00K | 4.22M | 2.23M | 2.65M | 3.33M |
| Earnings from Continuing Operations | 56.19 | 275.19 | 170.85 | 169.95 | 162.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.19M | 275.19M | 170.85M | 169.95M | 162.11M |
| EBIT | 27.22M | 252.84M | 149.11M | 152.24M | 148.68M |
| EBITDA | 28.05M | 253.67M | 150.07M | 153.21M | 149.64M |
| EPS Basic | 0.89 | 4.48 | 2.82 | 2.78 | 2.61 |
| Normalized Basic EPS | 0.57 | 2.84 | 1.79 | 1.77 | 1.66 |
| EPS Diluted | 0.76 | 4.21 | 2.66 | 2.62 | 2.44 |
| Normalized Diluted EPS | 0.48 | 2.67 | 1.69 | 1.67 | 1.56 |
| Average Basic Shares Outstanding | 248.37M | 246.26M | 244.32M | 241.73M | 237.20M |
| Average Diluted Shares Outstanding | 252.44M | 253.08M | 248.46M | 245.88M | 241.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |